Addex Therapeutics (ADXN) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Addex Therapeutics is the larger company by market cap ($6.1 million vs $5.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADXN | TOVX |
|---|---|---|
| Share price | $3.47 | $0.12 |
| Market cap | $6.08M | $5.51M |
| 1-day change | +2.06% | -6.25% |
| YTD return | — | -42.86% |
| 1-year return | — | -45.45% |
| 5-year return | — | -99.86% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-7.56 | $1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-23.74M |
| 52-week high | $10.43 | $0.49 |
| 52-week low | $2.56 | $0.12 |
| Distance from 52-week high | -66.73% | -75.51% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1983.33% |
| Average volume | 383.35K | 2.02M |
| Shares outstanding | 1.75M | 45.89M |
| Employees | 3 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Addex Therapeutics
ADXN stock →Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ADXN vs TOVX FAQ
Which is bigger, Addex Therapeutics or Theriva Biologics?
Addex Therapeutics (ADXN) is larger, with a market capitalization of $6.08M compared with $5.51M for Theriva Biologics (TOVX).
Are Addex Therapeutics and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.